Table 2.

Events in eligible participants for the nirsevimab effectiveness study during the five-month follow-up in the Madrid region.

Events in eligible participants for the study of nirsevimab effectiveness (N = 37,067)
	Inmunized against RSV at events time		Non-immunized at events time		Total number	p value
	Number	Frequency (%)	Number	Frequency (%)
Care required during the episodes
Primary care	2,588	67.71	1,512	53.56	4,100	<0.001a
Emergency care	1,076	28.15	878	31.10	1,954
Hospitalization	133	3.48	376	13.32	509
Intensive care	25	0.65	57	2.02	82
Recurring episodes of RSV
Primary care	119	66.85	204	77.86	323	<0.001b
Emergency care	59	33.15	58	22.14	117
Hospitalization	0	0.00	0	0.00	0	NA
Intensive care	0	0.00	0	0.00	0	NA
Age in months of cases: Median (IQR)
Primary care	5.65 (3.01)		5.26 (3.65)		5.36 (3.48)	<0.001c
Emergency care	3.97 (3.88)		4.95 (3.33)		4.33 (3.81)	<0.001c
Hospitalization	2.28 (2.89)		4.37 (3.55)		3.39 (3.61)	<0.001c
Intensive care	1.74 (1.96)		2.86 (3.70)		2.14 (2.73)	0.0220c

^aCochran-Armitage test for trend across ordered groups.

^bChi square test, table 2 × 2 or table r x 2. r = 1, 2, ..., n (number of rows).

^cWilcoxon rank-sum test.

NA, not available.